TROV Stock UPDATES Trovagene Inc (TROV) 3.00 08/02/2014 14:3
Post# of 273250
Posted On: 08/02/2014 3:39:52 PM
Trovagene Inc (TROV) 3.00 $TROV
Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Jul 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the second quarter and the six months ended June 30, 2014 on Thursday, August 7, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance
PR Newswire - Tue Jul 01, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from Silicon Valley Bank and Oxford Finance LLC. The additional capital will be used to support ongoing development and commercialization activities for the Company's precision cancer monitoring platform. As a result, Trovagene expects to report approximately $35 million in cash and cash equivalents for the quarter ended June 30, 2014.
Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute
PR Newswire - Mon Jun 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.
Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute
PR Newswire - Mon Jun 16, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.
Oncogene Mutation Signal in Urinary Cell Free DNA is Highly Correlated with Treatment Response
PR Newswire - Mon Jun 02, 11:45AM CDT
Trovagene, Inc. (NASDAQ: TROV), today announced that data from a study published in the 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology, demonstrates that oncogene mutation load in urinary cell-free DNA, as determined using the company's precision cancer monitoring technology, is significantly correlated with treatment response. The submission, by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, is titled "Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers."
Trovagene to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed May 28, 3:05PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference.
Trovagene's Precision Cancer Monitoring Technology Referenced in Multi-Disciplinary Clinical Consensus Guidelines
PR Newswire - Wed May 28, 8:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that the multi-disciplinary clinical consensus guidelines for Erdheim-Chester disease (ECD), recently published online in the journal Blood, reference the ability of the Company's precision cancer monitoring technology to detect actionable oncogene mutation status and monitor patients during treatment.
Ophthotech (OPHT) Jumps: Stock Rises 24.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 21, 7:51AM CDT
Ophthotech Corporation (OPHT) was a big mover last session, as its shares rose nearly 25% on the day.
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting
PR Newswire - Tue Apr 01, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Trovagene names Dr Charles Cantor to SAB
M2 - Thu Mar 27, 6:10AM CDT
Molecular diagnostics company Trovagene (NASDAQ:TROV) disclosed on Wednesday that Charles Cantor PhD, has been elected to its Scientific Advisory Board (SAB).
Genomics and Molecular Diagnostics Pioneer Charles Cantor, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Mar 26, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.
Trovagene and Catholic Health Initiatives Center for Translational Research Partner to Clinically Evaluate Non-Invasive Genomic Diagnostics to Improve Cancer Care
PR Newswire - Wed Mar 19, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into a strategic partnership to conduct clinical validation studies, clinical utility studies, health economic studies, and other activities to determine the effectiveness of Trovagene's urine-based cell-free DNA cancer monitoring diagnostics in clinical practice. CTR is a limited liability company whose sole corporate member is Catholic Health Initiatives Institute for Research and Innovation (CIRI), a direct subsidiary of Catholic Health Initiatives (CHI). Englewood Colorado-based CHI is one of the nation's largest health systems, operating in 18 states and comprising 87 hospitals, including four academic medical centers and teaching hospitals and 24 critical-access facilities.
Trovagene, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 17, 3:00PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.
Trovagene Releases Its First Oncogene Mutation Assay Using Next Generation Sequencing, Expands Its Non-Invasive Cancer Monitoring Platform
PR Newswire - Mon Mar 17, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed oncogene mutation assay, integrating the Company's proprietary sample preparation and primer technologies with next-generation sequencing (NGS) as a mutation detection platform.
Trovagene Schedules Release of Fourth Quarter and Year End 2013 Financial Results and Investor Conference Call
PR Newswire - Mon Mar 03, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
3 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 28, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dr. Rodney S. Markin Joins Trovagene's Board of Directors
PR Newswire - Wed Feb 19, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company's Board of Directors. Dr. Markin is a hepatic pathologist by training, and is a leading authority in the field of laboratory automation.
Trovagene to Present at Two Upcoming Investor Conferences
PR Newswire - Thu Feb 06, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference.
Nasdaq stocks posting largest percentage decreases
AP - Mon Feb 03, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer
PR Newswire - Mon Jan 06, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of experienced investigators and clinical staff who specialize in Phase I through Phase IV oncology clinical trials. In addition to the 11 US Oncology Research affiliated community cancer care sites participating in this study, academic research institutions that specialize in oncology have also elected to participate.
Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Jul 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the second quarter and the six months ended June 30, 2014 on Thursday, August 7, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance
PR Newswire - Tue Jul 01, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from Silicon Valley Bank and Oxford Finance LLC. The additional capital will be used to support ongoing development and commercialization activities for the Company's precision cancer monitoring platform. As a result, Trovagene expects to report approximately $35 million in cash and cash equivalents for the quarter ended June 30, 2014.
Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute
PR Newswire - Mon Jun 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.
Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute
PR Newswire - Mon Jun 16, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.
Oncogene Mutation Signal in Urinary Cell Free DNA is Highly Correlated with Treatment Response
PR Newswire - Mon Jun 02, 11:45AM CDT
Trovagene, Inc. (NASDAQ: TROV), today announced that data from a study published in the 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology, demonstrates that oncogene mutation load in urinary cell-free DNA, as determined using the company's precision cancer monitoring technology, is significantly correlated with treatment response. The submission, by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, is titled "Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers."
Trovagene to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed May 28, 3:05PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference.
Trovagene's Precision Cancer Monitoring Technology Referenced in Multi-Disciplinary Clinical Consensus Guidelines
PR Newswire - Wed May 28, 8:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that the multi-disciplinary clinical consensus guidelines for Erdheim-Chester disease (ECD), recently published online in the journal Blood, reference the ability of the Company's precision cancer monitoring technology to detect actionable oncogene mutation status and monitor patients during treatment.
Ophthotech (OPHT) Jumps: Stock Rises 24.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 21, 7:51AM CDT
Ophthotech Corporation (OPHT) was a big mover last session, as its shares rose nearly 25% on the day.
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting
PR Newswire - Tue Apr 01, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
Trovagene names Dr Charles Cantor to SAB
M2 - Thu Mar 27, 6:10AM CDT
Molecular diagnostics company Trovagene (NASDAQ:TROV) disclosed on Wednesday that Charles Cantor PhD, has been elected to its Scientific Advisory Board (SAB).
Genomics and Molecular Diagnostics Pioneer Charles Cantor, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Mar 26, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.
Trovagene and Catholic Health Initiatives Center for Translational Research Partner to Clinically Evaluate Non-Invasive Genomic Diagnostics to Improve Cancer Care
PR Newswire - Wed Mar 19, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into a strategic partnership to conduct clinical validation studies, clinical utility studies, health economic studies, and other activities to determine the effectiveness of Trovagene's urine-based cell-free DNA cancer monitoring diagnostics in clinical practice. CTR is a limited liability company whose sole corporate member is Catholic Health Initiatives Institute for Research and Innovation (CIRI), a direct subsidiary of Catholic Health Initiatives (CHI). Englewood Colorado-based CHI is one of the nation's largest health systems, operating in 18 states and comprising 87 hospitals, including four academic medical centers and teaching hospitals and 24 critical-access facilities.
Trovagene, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 17, 3:00PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.
Trovagene Releases Its First Oncogene Mutation Assay Using Next Generation Sequencing, Expands Its Non-Invasive Cancer Monitoring Platform
PR Newswire - Mon Mar 17, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed oncogene mutation assay, integrating the Company's proprietary sample preparation and primer technologies with next-generation sequencing (NGS) as a mutation detection platform.
Trovagene Schedules Release of Fourth Quarter and Year End 2013 Financial Results and Investor Conference Call
PR Newswire - Mon Mar 03, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
3 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 28, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Dr. Rodney S. Markin Joins Trovagene's Board of Directors
PR Newswire - Wed Feb 19, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Dr. Rodney S. Markin has joined the Company's Board of Directors. Dr. Markin is a hepatic pathologist by training, and is a leading authority in the field of laboratory automation.
Trovagene to Present at Two Upcoming Investor Conferences
PR Newswire - Thu Feb 06, 7:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2014 healthcare and investor conferences next week in New York: BIO CEO & Investor Conference and Leerink Global Healthcare Conference.
Nasdaq stocks posting largest percentage decreases
AP - Mon Feb 03, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Trovagene and US Oncology Research Collaborate on a Prospective Study for Urine-based KRAS Testing in Patients with Metastatic Pancreatic Cancer
PR Newswire - Mon Jan 06, 4:00AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of experienced investigators and clinical staff who specialize in Phase I through Phase IV oncology clinical trials. In addition to the 11 US Oncology Research affiliated community cancer care sites participating in this study, academic research institutions that specialize in oncology have also elected to participate.
(0)
(0)Scroll down for more posts ▼